Vanda Pharmaceuticals (VNDA) vs Vogenx (VOGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vanda Pharmaceuticals is the larger company by market cap ($276.3 million vs $260.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VNDA | VOGX |
|---|---|---|
| Share price | $4.57 | $17.56 |
| Market cap | $276.31M | $260.86M |
| 1-day change | +0.88% | +0.40% |
| YTD return | -48.19% | — |
| 1-year return | -16.15% | — |
| 5-year return | -75.39% | — |
| Forward P/E | 22.85 | — |
| EPS (TTM) | $-4.63 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.94 | $38.41 |
| 52-week low | $4.27 | $12.95 |
| Distance from 52-week high | -54.02% | -54.28% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +157.11% | +213.21% |
| Average volume | 974.13K | 187.66K |
| Shares outstanding | 60.46M | 14.86M |
| Employees | 533 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
About Vogenx
VOGX stock →Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
VNDA vs VOGX FAQ
Which is bigger, Vanda Pharmaceuticals or Vogenx?
Vanda Pharmaceuticals (VNDA) is larger, with a market capitalization of $276.31M compared with $260.86M for Vogenx (VOGX).
Are Vanda Pharmaceuticals and Vogenx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.